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The GRACE score is currently the most widely used model to
assess patient prognosis after myocardial infarction (MI). We
have demonstrated that the prognostic performance of the
GRACE score can be improved by adding blood biomarkers
measured routinely at hospital admission in our study recently
published in the International Journal of Cardiology: “Addition
of routinely measured blood biomarkers signiﬁcantly improves
GRACE risk stratiﬁcation in patients with myocardial
infarction”.
In this Data-in-Brief article we present additional original
data from our dataset. This dataset consists of clinical and bio-
marker information and follow-up data of 2055 conﬁrmed MI
patients. In 143 of these patients the endpoint (all-cause mor-
tality or reMI) occurred during six months follow-up. We
describe the differences in baseline characteristics between ST-
elevation MI (STEMI) patients and non-STEMI patients, differ-
ences in biomarker levels at admission between patients in
whom the endpoint occurred and patients who remained
endpoint-free, and associations of the biomarkers with the
endpoint. Moreover, we show additional statistical results ofvier Inc. This is an open access article under the CC BY license
.ijcard.2018.07.100
M. Umans).
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V.J. van den Berg et al. / Data in Brief 21 (2018) 371–376372analyses that compare the original GRACE-only model with our
extended GRACE/biomarker model.
& 2018 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Speciﬁcations tableubject area Clinical cardiology
ore speciﬁc subject area Myocardial infarction, acute coronary syndrome
ype of data Table, ﬁgures
ow data was acquired From a prospective database consisting of all patients treated for
myocardial infarction in the Northwest Clinics, the Netherlands,
between 2013 and 2016. Missing data were completed and clinical
outcomes were added retrospectively.ata format Filtered and analyzed
xperimental factors N/A
xperimental features Summary statistics and AUCs for different biomarkers
ata source location Alkmaar, the Netherlands
ata accessibility Data is with this article and not in a public repositoryD
Value of the data
 Data from our cohort recently published in the related research article shows that the ability of the
GRACE score for detecting MI patients at high risk for mortality or MI within 6 months, can be
signiﬁcantly improved by adding several biomarkers measured routinely at admission.
 Our large cohort provides insights into current prognosis after treatment for myocardial
infarctions.
 This data-in-brief shows the differences in clinical characteristics between patients with ST-
elevation myocardial infarction and patients with myocardial infarction without ST-elevation.
 The data shows associations for many common biomarkers and clinical outcomes in patients with
myocardial infarctions. In addition, corresponding AUCs for each biomarker are provided.
 Subgroup analyses demonstrate that biomarkers are incremental to GRACE in all examined subsets
of patients.1. Data
The data shared is generated from a large prospective dataset containing all consecutive hospi-
talizations for myocardial infarctions (MI) between 2013 and 2016 from the Northwest Clinics. In this
data, we have correlated patient characteristics and biomarker data with clinical outcomes. Here we
show the details from our statistical analysis that resulted in an improved prognostic model for MI
patients.
– Table 1: Baseline characteristics of ST-elevation MI (STEMI) patients and non-STEMI patients
separately.
– Table 2: Average biomarker values in the entire cohort, in patients in whom the endpoint occurred
and in endpoint-free patients.
– Table 3: Associations between patients characteristics, biomarkers and clinical outcome at six
months. We also added the corresponding AUCs.
V.J. van den Berg et al. / Data in Brief 21 (2018) 371–376 373– Fig. 1 Depicts the differences in estimated risk from the GRACE-only model and the GRACE model
extended with available biomarker data.
– Table 4: Comparison of the performance of the GRACE-only model and GRACE model extended
with available biomarker data. The performance is compared in the entire cohort and in different
subgroups of the cohort.Table 1
Baseline characteristics for myocardial infarction patients with or without ST-elevation.
NSTEMI (N ¼ 1078) STEMI (N ¼ 977) p-value
Age 68.8 (12.6) 65.3 (12.8) o0.001
Male gender, n (%) 708 (65.7) 687 (70.3) 0.028
Risk factors, n (%)
None 111 (11.0) 118 (12.7) 0.277
Hypertension 541 (53.5) 360 (38.7) o0.001
Hypercholesterolemia 344 (34.0) 248 (26.6) o0.001
Family history of CAD 400 (39.6) 377 (40.5) 0.710
Diabetes, IDDM 76 (7.5) 28 (3.0) o0.001
Diabetes, NIDDM 121 (12.0) 78 (8.4) 0.011
Current smoker 322 (31.8) 417 (44.8) o0.001
Cardiovascular disease history, n (%)
MI 204 (25.0) 92 (12.1) o0.001
PCI 190 (23.4) 80 (10.5) o0.001
CABG 71 (8.7) 19 (2.5) o0.001
Stroke/TIA 54 (6.6) 23 (3.0) 0.001
Admission infarct
Highest troponin I, ug/L 2.05 (0.39, 7.35) 24.54 (6.75, 68.17) o0.001
Highest CK, U/L 170 (92, 401) 803 (382, 2079) o0.001
Days in hospital 3 (2., 4) 2 (2, 3) o0.001
GRACE and individual components
GRACE risk score 141 (116, 165) 170 (146, 195) o0.001
Systolic blood pressure, mmHg 145 (25) 127 (24) o0.001
Heart rate, beats/min 70 (63, 83) 71 (63, 80) 0.968
Creatinin, mol/L 84 (72, 101) 80 (69, 94) o0.001
Killip class I,% (N) 991 (91.9) 911 (93.2) 0.007
ST deviation 250 (23.2) 977 (100.0) o0.001
Elevated cardiac enzymes 865 (80.2) 722 (73.9) 0.001
Cardiac arrest 13 (1.2) 60 (6.1) o0.001
Imaging, n (%)
No visible CAD 93 (9.7) 10 (1.0) overall
o0.001
1 vessel 351 (36.7) 476 (49.7)
2 vessels 237 (24.8) 261 (27.2)
3 vessels 240 (25.1) 195 (20.4)
Left main 36 (3.8) 16 (1.7)
Percutaneous intervention, % (n)
Left main 24 (3.4) 11 (1.2) 0.005
Left anterior descending artery 309 (43.8) 397 (43.9) 1.000
Left circumﬂex artery 200 (28.4) 144 (15.9) o0.001
Right coronary artery 209 (29.6) 369 (40.8) o0.001
a ¼ mean (standard deviation).
b ¼ median (25th, 75th percentile).
c ¼ measured every six hours during admission until the value starts to lower.
Categorical variables for cases and non-cases were compared using chi-square or Fisher's exact test, whichever was appro-
priate. Differences for continuous variables in the same groups were tested using the student t-test for normally distributed
variables and Mann-Whitney test for non-normally distributed variables.
Table 2
Median biomarker levels.
Biomarker, unit Reference
values
Median
values (IQR)
No event,
n ¼ 1912
Event,
n ¼ 143
P-value
Troponin I, ug/L (0.00, 0.04) 0.15 (0.05, 0.76) 0.14 (0.05, 0.69) 0.34 (0.07, 1.63) o0.001
Creatine kinase, U/L (0, 171) 124 (78, 210) 124 (80, 209.25) 110 (65, 215) 0.068
C-reactive protein, mg/L (0, 5) 2.8 (1.2, 6.5) 2.6 (1.2, 6.0) 6.6 (2.7, 24.0) o0.001
ASAT, U/L (0, 35) 25 (18, 37) 24 (18, 36) 25 (18, 43) 0.348
ALAT, U/L (0, 45) 23 (17, 32) 23 (17, 32) 22 (16, 30) 0.225
Alkalic phosphatase, U/L (0, 120) 72 (60, 87) 72 (60, 87) 77 (65, 97) o0.001
Gamma-glutamyltransferase, U/L (0, 55) 28 (19, 43) 27 (19, 42) 31 (23, 51) 0.009
Cholesterol, mmol/L (0.0, 6.4) 5.1 (4.3, 6.0) 5.2 (4.3, 6.0) 4.6 (3.5, 5.6) o0.001
Triglycerides, mmol/L (0.6, 2.2) 1.3 (0.8, 2.0) 1.3 (0.8, 2.0) 1.2 (0.9, 1.9) 0.814
HDL cholesterol, mmol/L (0.9, 1.7) 1.2 (1.0, 1.4) 1.2 (1.0, 1.4) 1.1 (1.0, 1.4) 0.309
LDL cholesterol, mmol/L (1.5, 4.5) 3.3 (2.4, 4.1) 3.3 (2.5, 4.1) 2.6 (1.8, 3.7) o0.001
Sodium, mmol/L (134, 145) 137 (136, 139) 137 (136, 139) 137 (135, 139) 0.001
Potassium, mmol/L (3.4, 4.9) 3.9 (3.6, 4.2) 3.9 (3.6, 4.1) 4.0 (3.8, 4.5) o0.001
Glucose, mmol/L (3.3, 7.8) 7.8 (6.5, 9.6) 7.8 (6.5, 9.5) 8.3 (6.8, 11.2) 0.002
Urea, mmol/L (2.0, 8.0) 6.0 (4.9, 7.5) 5.9 (4.8, 7.3) 8.0 (6.0, 11.0) o0.001
Hemoglobin, mmol/L (8.5, 11.0)a 8.7 (8.1, 9.3) 8.8 (8.1, 9.3) 8.1 (7.3, 8.8) o0.001
Thrombocytes, 10^9/L (150, 400) 237 (200, 284) 238 (201, 285) 230 (194, 278) 0.097
Leukocytes, 10^9/L (4.0, 10.0) 9.3 (7.4, 11.8) 9.3 (7.3, 11.8) 9.6 (7.5, 12.1) 0.386
LDL: low-density lipoprotein; HDL: high-density lipoprotein; ASAT: aspartate aminotransferase; ALAT: alanine amino-
transferase;
U/L: units per liter; Mmol/L: millimol per liter; ug/L: microgram per liter; mg/L: milligram per liter.
a Reference value for males, for females the reference value is 7.5–10.0mmol/L.
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From our prospective hospital dataset, we have retrieved the data on all hospitalizations for MI
between 2013 and 2016. From this hospitalization set, we selected all unique patients that were
directly sent to the Northwest Clinics for treatment and ensuing admission. Patients referred to our
hospital solely for revascularization were thus excluded. In addition, we excluded patients that
transferred to other hospitals outside of our region for further (outpatient) treatment before six
months of follow-up. For patients that were treated for MI multiple times during 2013 and 2016, the
ﬁrst admission with complete blood proﬁle was chosen as the index admission.
For all patients, we had a complete biomarker proﬁle, consisting of 19 established biomarkers
measured upon admission: Troponine I, creatine kinase, C-reactive protein, urea, creatinine, sodium,
potassium, ASAT, ALAT, alkaline phosphatase, Gamma-GT, total cholesterol, high-density lipoprotein
cholesterol, triglycerides, glucose, low-density lipoprotein cholesterol, leukocytes, hemoglobin and
thrombocytes. Moreover, for all patients the admission-GRACE score was calculated. This score is used
to calculate the risk of re-MI or all-cause mortality within six month after the index MI [1,2].
In total, the data consist of the information of 2055 patients admitted for MI. Of these patients, 977
suffered a STEMI and 1078 a NSTEMI. Table 1 shows the differences in baseline characteristics
between STEMI and NSTEMI patients. STEMI patients were on average younger, more often male,
smoked more but otherwise had less risk factors than NSTEMI patients. STEMI patients also less often
had a history of cardiovascular disease and a much higher GRACE score.
The endpoint occurred in 143 patients during the 6 months follow-up. In Table 2 the differences in
average biomarker levels between cases and non-cases are shown. We also calculated, using logistic
regression, the odds ratio per unit increase for experiencing the endpoint for all available biomarkers
(Table 3). In addition, we added the odds ratios for each separate component of the GRACE-score.
Finally, using the odds ratios, we calculated AUCs to be able to compare prognostic values of both the
clinical characteristics and the biomarker data. An overview of the odds ratios and AUCs are shown in
Table 3.
Table 3
Associations between clinical characteristics and biomarkers measured at admission and clinical outcomes during 6 months of
follow-up.
Entire cohort n ¼ 2055
(143 events)
STEMI patients n ¼ 977
(58 events)
NSTEMI patients n ¼ 1078
(85 events)
OR (95%CI) AUC OR (95%CI) AUC OR (95%CI) AUC
Clinical variables, unit of increase
Systolic blood pressure, 10mm Hg 0.96 (0.89, 1.02) 0.54 0.98 (0.87, 1.09) 0.55 0.90 (0.82, 0.99) 0.57
Heart rate, 10 bpm 1.26 (1.16, 1.37) 0.61 1.37 (1.19, 1.57) 0.62 1.19 (1.06, 1.33) 0.60
Killip class, class 3.33 (2.47, 4.50) 0.61 3.17 (2.15, 4.72) 0.60 3.66 (2.32, 5.72) 0.61
Elevated cardiac enzymes, yes 1.58 (1.02, 2.56) 0.54 1.54 (0.82, 3.18) 0.54 1.54 (0.85, 3.04) 0.53
Cardiac arrest, yes 0.56 (0.14, 1.54) 0.51 0.53 (0.09, 1.76) 0.51 0.97 (0.05, 5.03) 0.50
Biomarkers measured at admission, unit of increase
Troponin I, 100 ug/L 1.14 (0.36, 2.00) 0.59 1.25 (0.43, 2.20) 0.62 1.15 (1.08, 1.24) 0.56
Creatine kinase, 100 U/L 0.97 (0.91, 1.02) 0.55 1.02 (0.96, 1.07) 0.51 0.82 (0.67, 0.96) 0.58
C-reactive protein, 10mg/L 1.14 (1.09, 1.19) 0.69 1.13 (1.07, 1.20) 0.72 1.16 (1.08, 1.24) 0.66
ASAT, 100 U/L 1.17 (0.92, 1.42) 0.52 1.34 (1.05, 1.66) 0.61 0.59 (0.20, 1.18) 0.51
ALAT, 100 U/L 1.14 (0.77, 1.50) 0.53 1.28 (0.94, 1.80) 0.57 0.07 (0.01, 0.52) 0.60
Alkalic phosphatase, 100 U/L 2.93 (1.84, 4.75) 0.59 2.76 (1.28, 6.53) 0.59 2.96 (1.66, 5.37) 0.59
Gamma-glutamyltransferase, 100 U/L 1.16 (0.91, 1.42) 0.57 1.64 (1.07, 2.39) 0.61 1.03 (0.63, 1.32) 0.54
Cholesterol, 1mmol/L 0.71 (0.61, 0.82) 0.62 0.62 (0.48, 0.80) 0.63 0.77 (0.64, 0.92) 0.60
Triglycerides, 1mmol/L 0.99 (0.82, 1.19) 0.51 0.94 (0.66, 1.29) 0.52 0.95 (0.74, 1.20) 0.50
HDL cholesterol, 1mmol/L 0.96 (0.55, 1.63) 0.53 1.16 (0.46, 2.76) 0.51 0.82 (0.41, 1.60) 0.55
LDL cholesterol, 1mmol/L 0.68 (0.58, 0.80) 0.63 0.58 (0.44, 0.76) 0.65 0.77 (0.63, 0.93) 0.60
Sodium, 1mmol/L 0.89 (0.84, 0.94) 0.58 0.88 (0.81, 0.96) 0.60 0.88 (0.82, 0.94) 0.59
Potassium, 1mmol/L 2.37 (1.73, 3.25) 0.62 3.18 (1.83, 5.47) 0.62 1.99 (1.33, 2.98) 0.61
Glucose, 1mmol/L 1.12 (1.07, 1.16) 0.58 1.16 (1.09, 1.24) 0.60 1.10 (1.04, 1.16) 0.58
Urea, 1mmol/L 1.26 (1.21, 1.32) 0.71 1.31 (1.21, 1.42) 0.67 1.24 (1.18, 1.31) 0.73
Creatinin, 10mg/mmol 1.13 (1.10, 1.18) 0.69 1.27 (1.18, 1.37) 0.69 1.09 (1.05, 1.14) 0.69
Hemoglobin, 1mmol/L 0.48 (0.40, 0.57) 0.68 0.55 (0.42, 0.72) 0.65 0.44 (0.35, 0.55) 0.71
Thrombocytes, 10^11/L 0.92 (0.71, 1.15) 0.54 1.27 (0.90, 1.72) 0.51 0.71 (0.49, 0.99) 0.57
Leukocytes, 10^9/L 1.01 (0.97, 1.04) 0.52 1.03 (0.96, 1.10) 0.53 1.01 (0.96, 1.05) 0.54
LDL: low-density lipoprotein; HDL: high-density lipoprotein; ASAT: aspartate aminotransferase; ALAT: alanine amino-
transferase; n ¼ number; OR: odds ratio; 95%CI: 95% conﬁdence interval; U/L: units per liter; Mmol/L: millimol per liter; ug/L:
microgram per liter; mg/L: milligram per liter; STEMI: ST-elevation myocardial infarction; NSTEMI: non ST-elevation myo-
cardial infarction.
Fig. 1. Predicted risks. Grey squares are patients without an event in 6 months after hospitalization for MI Black squares are
patients with an event in 6 months after hospitalization for MI.
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Table 4
Performance of GRACE-only model and full model in different subcategories.
Cohort No. of patients No. of events Area under ROC-curve
GRACE-only model Extended GRACE model
Full cohort 2055 143 0.70 0.76
STEMI 977 58 0.71 0.74
NSTEMI 1078 85 0.75 0.79
Male 1395 86 0.66 0.72
Female 660 57 0.74 0.82
Age 65 or lower 906 24 0.59 0.61
Age above 65 1149 119 0.65 0.74
No.: number; STEMI: ST-elevation myocardial infarction; NSTEMI: Non ST-elevation myocardial infarction; Extended GRACE
model: model containing the GRACE risk score and admission levels of the following blood biomarkers: urea, sodium,
potassium, alkaline phosphatase, LDL cholesterol, glucose, hemoglobin and C-reactive protein.
V.J. van den Berg et al. / Data in Brief 21 (2018) 371–376376Finally, we extended the GRACE-score by adding the available biomarkers from our dataset in
order to improve its prognostic value [3]. In our new extended model, the following biomarkers were
included: urea, sodium, potassium, alkaline phosphatase, LDL cholesterol, glucose, hemoglobin and C-
reactive protein. The distribution of the predictions for each patient for the GRACE-only model and
the extended GRACE model are depicted in Fig. 1. Table 4 shows the AUCs for the two models in the
total cohort as well as in different subgroups of the total cohort.Acknowledgements
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